Fujita Shigeki, Morii Eiichi, Rahadiani Nur, Wada Naoki, Hori Yumiko, Ikeda Jun-Ichiro, Aozasa Katsuyuki
Department of Pathology, Osaka University Graduate School of Medicine, Suita 565-0871, Japan.
Exp Ther Med. 2011 Jul;2(4):591-594. doi: 10.3892/etm.2011.269. Epub 2011 May 12.
Aldehyde dehydrogenase (ALDH) 1 is expressed in various stem/progenitor cells, including cancer-initiating cells (CICs). In the present study, ALDH1 expression was immunohistochemically examined in diffuse large B-cell lymphoma (DLBCL). Unexpectedly, ALDH1 expression was occasionally detected in stromal cells, but not in lymphoma cells. Positively stained cells were CD68(+) cells with voluminous cytoplasm and fascin(+) cells with reticular morphology, designated as macrophages and dendritic cells (DCs), respectively. The presence of ALDH1(+) macrophages was not correlated with stage, response to therapies and prognosis. However, cases with ALDH1(+) DCs were mostly nodal, which showed a poorer response to therapies and a worse overall survival rate than cases without ALDH1(+) DCs. The presence of ALDH1(+) DCs appears to be involved in the malignant potential of DLBCL in lymph node.
醛脱氢酶（ALDH）1在包括癌症起始细胞（CIC）在内的多种干/祖细胞中表达。在本研究中，采用免疫组织化学方法检测弥漫性大B细胞淋巴瘤（DLBCL）中ALDH1的表达。出乎意料的是，ALDH1表达偶尔在基质细胞中检测到，而在淋巴瘤细胞中未检测到。阳性染色细胞分别为具有丰富细胞质的CD68（+）细胞和具有网状形态的fascin（+）细胞，分别被指定为巨噬细胞和树突状细胞（DC）。ALDH1（+）巨噬细胞的存在与分期、治疗反应和预后无关。然而，有ALDH1（+）DC的病例大多为淋巴结受累，与没有ALDH1（+）DC的病例相比，其对治疗的反应较差，总生存率更低。ALDH1（+）DC的存在似乎与DLBCL在淋巴结中的恶性潜能有关。
